Clinical Drug Investigation

, Volume 25, Issue 11, pp 731–740 | Cite as

Lack of Pharmacokinetic Interaction between Esomeprazole and the Nonsteroidal Anti-Inflammatory Drugs Naproxen and Rofecoxib in Healthy Subjects

  • M. Hassan-Alin
  • J. Naesdal
  • C. Nilsson-Pieschl
  • G. Långström
  • T. Andersson
Original Research Article


Background: We investigated the potential interactions between esomeprazole and a non-selective nonsteroidal anti-inflammatory drug (NSAID; naproxen) or a cyclo-oxygenase (COX)-2-selective NSAID (rofecoxib) in healthy subjects.

Methods: Two studies of identical randomised, open, three-way crossover design were conducted. Subjects (n = 32 for both studies) were to receive 1 week’s treatment with esomeprazole 40mg once daily (studies A and B), naproxen 250mg twice daily (study A), rofecoxib 12.5mg once daily (study B), and esomeprazole in combination with naproxen (study A) or rofecoxib (study B). Study periods were separated by a 2-week washout period.

Results: On day 7 of dosing, the ratios (and 95% CIs) for the area under the plasma concentration-time curve during the dosing interval (AUCτ) and observed maximum plasma concentration (Cmax) of esomeprazole and NSAID combination/NSAID alone were 0.98 (0.94, 1.01) and 1.00 (0.97, 1.04), respectively, for study A, and 1.15 (1.06, 1.24) and 1.14 (1.02, 1.28), respectively, for study B. The ratios (and 95% CIs) for AUCτ and Cmax of esomeprazole and NSAID combination/esomeprazole alone were 0.96 (0.89, 1.03) and 0.92 (0.85, 1.00), respectively, for study A, and 1.05 (0.96, 1.15) and 1.05 (0.94, 1.18), respectively, for study B. All treatments were well tolerated during the study period.

Conclusion: Naproxen and rofecoxib do not interact with esomeprazole, and esomeprazole does not affect the pharmacokinetics of naproxen or rofecoxib. These findings indicate that esomeprazole can be used in combination with NSAIDs without the risk of a pharmacokinetic interaction.


Celecoxib Naproxen Rofecoxib Esomeprazole Valdecoxib 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The study was sponsored by AstraZeneca R&D Mölndal, Mölndal, Sweden.


  1. 1.
    Retail & Provider Perspective, National Prescription Audit, 1999–2000. Plymouth (PA): IMS Health, 2000Google Scholar
  2. 2.
    Wolfe F, Kleinheksel SM, Spitz PW, et al. A multicentre study of hospitalization in rheumatoid arthritis: frequency, medical-surgical admissions, and charges. Arthritis Rheum 1986; 29: 614–9PubMedCrossRefGoogle Scholar
  3. 3.
    Hazleman BL. Incidence of gastropathy in destructive arthropathies. Scand J Rheumatol Suppl 1989; 78: 1–4PubMedCrossRefGoogle Scholar
  4. 4.
    Griffin MR. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastroduodenal injury. Am J Med 1998; 104(3A): 23S–9SPubMedCrossRefGoogle Scholar
  5. 5.
    Hirschowitz BI. Non-steroidal anti-inflammatory drugs and the gastrointestinal tract. Gastroenterologist 1994; 2: 207–23PubMedGoogle Scholar
  6. 6.
    Hawkey CJ. Non-steroidal anti-inflammatory drugs and peptic ulcers. BMJ 1990; 300: 278–84PubMedCrossRefGoogle Scholar
  7. 7.
    Myerson RM. NSAID-associated gastroduodenal damage. J Pharm Med 1992; 2: 277–84Google Scholar
  8. 8.
    Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998; 105(1B): 31S–8SPubMedCrossRefGoogle Scholar
  9. 9.
    Bombardier C, Laine L, Reicin A, et al. VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520–8PubMedCrossRefGoogle Scholar
  10. 10.
    Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS Study: a randomized controlled trial. JAMA 2000; 284: 1247–55PubMedCrossRefGoogle Scholar
  11. 11.
    Lenzer J. Pfizer is asked to suspend sales of painkiller [news item]. BMJ 2005; 330: 862PubMedCrossRefGoogle Scholar
  12. 12.
    Young D. FDA ponders future of NSAIDS: Pfizer reluctantly withdraws Bextra. Am J Health Syst Pharm 2005; 62: 997–1000PubMedGoogle Scholar
  13. 13.
    US Food and Drug Administration. COX-2 selective (includes Bextra, Celebrex and Vioxx) and non-selective non-selectivel non-steroidal anti-inflammatory drugs (NSAIDs) [online]. Available from URL: [Accessed 2005 Sep 5]
  14. 14.
    European Medicines Agency Post-authorisation of Medicines for Human Use. Questions and answers on celecoxib/COX-2 inhibitors [online]. Available from URL: [Accessed 2005 Sep 5]
  15. 15.
    Kuehn BM. FDA panel: keep COX-2 drugs on market: black box for COX-2 labels, caution urged for all NSAIDs. JAMA 2005; 292: 1571–2CrossRefGoogle Scholar
  16. 16.
    Young D. FDA labors over NSAID decisions: panel suggests COX-2 inhibitors stay available. Am J Health Syst Pharm 2005; 62: 668–72PubMedGoogle Scholar
  17. 17.
    Murray S. Health Canada lukewarm on Vioxx panel findings [news item]. CMAJ 2005; 173: 350PubMedGoogle Scholar
  18. 18.
    Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with non-steroidal anti-inflammatory drugs. N Engl J Med 1998; 338: 719–26PubMedCrossRefGoogle Scholar
  19. 19.
    Hawkey CJ, Karrasch JA, Szczepañski L, et al. Omeprazole compared with misoprostol for ulcers associated with non-steroidal anti-inflammatory drugs. N Engl J Med 1998; 338: 727–34PubMedCrossRefGoogle Scholar
  20. 20.
    Elliott SL, Ferris RJ, Giraud AS, et al. Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH. Clin Exp Pharmacol Physiol 1996; 23: 432–4PubMedCrossRefGoogle Scholar
  21. 21.
    Röhss K, Wilder-Smith C, Claar-Nilsson C, et al. Esomeprazole 40mg provides more effective acid control than standard doses of all other proton pump inhibitors [abstract]. Gut 2001; 49Suppl. III: 2649Google Scholar
  22. 22.
    Lagerström PO, Persson BA. Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. J Chromatogr 1984; 309: 347–56PubMedCrossRefGoogle Scholar
  23. 23.
    Davies NM, Teng XW, Skjodt NM. Pharmacokinetics of rofecoxib: a specific cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2003; 42: 545–56PubMedCrossRefGoogle Scholar
  24. 24.
    Rodrigues AD. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab Dispos 2005, Aug 23; [Epub ahead of print]Google Scholar
  25. 25.
    Äbelö A, Andersson TB, Antonsson M, et al. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 2000; 28: 96–972Google Scholar
  26. 26.
    Leemann T D, Transon C, Bonnabry P, et al. A major role of cytochrome P450 TB (CYP2C subfamily) in the actions of non-steroidal anti-inflammatory drugs. Drugs Exp Clin Res 1993; 19: 189–95PubMedGoogle Scholar
  27. 27.
    Andersson T, Bredberg E, Lagerström PO, et al. Lack of drug-drug interaction between three different non-steroidal anti-inflammatory drugs and omeprazole. Eur J Clin Pharmacol 1998; 54: 399–404PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • M. Hassan-Alin
    • 1
  • J. Naesdal
    • 1
  • C. Nilsson-Pieschl
    • 1
  • G. Långström
    • 1
  • T. Andersson
    • 2
  1. 1.Clinical PharmacologyAstraZeneca R&D MölndalMölndalSweden
  2. 2.AstraZeneca LPWilmingtonUSA

Personalised recommendations